Boosted Engagement: Prominent Drug Companies Embrace Biden’s Medicare Price Negotiation Program

The White House announced on Tuesday that all 10 manufacturers of the first drugs selected for Medicare price negotiations will be participating in the process, despite some of them currently suing the administration to stop it.

Ahead of the October 1 deadline, many of the companies indicated their willingness to participate in the negotiations. The White House confirmed this news in its announcement, touting it as a political victory.

According to the White House, around 9 million Medicare enrollees spent $3.4 billion out of pocket on the selected drugs from companies like Johnson & Johnson, Merck, Bristol Myers Squibb, and AstraZeneca last year.

“For decades, Big Pharma fought to block Medicare from directly negotiating lower drug prices for seniors and other Medicare beneficiaries,” stated the White House. “President Biden and Congressional Democrats finally beat Big Pharma and allowed Medicare to directly negotiate lower drug prices by passing the Inflation Reduction Act.”

The drugs on the negotiation list are commonly used for treating or preventing conditions like heart disease and diabetes. Some of them include blood thinners such as Eliquis and Xarelto, diabetes medications like Januvia, Farxiga, and NovoLog, as well as Enbrel for rheumatoid arthritis.

Companies had until Sunday to decide whether they wanted to participate in the price negotiation program, and Monday was the deadline for them to submit manufacturer-specific information, including research and development costs, sales, and revenue data, to the administration.

The Centers for Medicare and Medicaid Services will send an initial offer to each company by February 1, and the negotiation process will continue until August 1. However, the negotiated prices will not take effect until 2026, and more companies will be added to the list in the future.

Since the passage of the Inflation Reduction Act last year, drugmakers have been actively opposing negotiation efforts, resulting in at least nine lawsuits filed across the country. Last week, a federal judge ruled against the U.S. Chamber of Commerce’s attempt to temporarily block the implementation of the negotiation process. However, the judge also denied the government’s motion to dismiss the case.

The companies argue that the negotiation process is unconstitutional and amounts to forced price fixing, which could lead to lower profits, reduced investment in research and development, and ultimately, fewer drugs available in the market.

The companies claim that their decision to participate in the negotiations is primarily driven by the lack of alternatives. Manufacturers that choose not to participate can withdraw all their products from Medicare and Medicaid coverage, but this would mean losing a significant income source.

Denial of responsibility! Vigour Times is an automatic aggregator of Global media. In each content, the hyperlink to the primary source is specified. All trademarks belong to their rightful owners, and all materials to their authors. For any complaint, please reach us at – [email protected]. We will take necessary action within 24 hours.